Growth, serum lipoproteins and apoproteins in infants with congenital nephrosis.
Retarded growth and extremely high cholesterol levels have been reported in infants with congenital nephrotic syndrome of the Finnish type (CNF). In an attempt to normalize growth and lipid disturbances the high-calorie diet (130 kcal/kg/d) containing protein 4 g/kg/d and supplemented with unsaturated fatty acids (mean P/S-ratio 1.40) was given to ten infants with CNF from birth. Growth, lipoprotein and apoprotein concentrations were measured. All patients exhibited normal growth, which allows renal transplantation, the only life-saving treatment in CNF, already at an early age. In spite of the diet lipid profiles at 3 and 9 months revealed marked elevation of triglyceride in all lipoproteins, especially in VLDL fraction, compared to controls. The abnormalities increased significantly with time (p for VLDL-TG 0.04). The elevation of serum cholesterol was mainly attributable to the increase of cholesterol in triglyceride-rich particles (chylomicrons, VLDL, IDL). Analysis of VLDL, LDL and HDL revealed significant triglyceride enrichment and cholesterol deficiency in all lipoproteins. The concentrations of the low-molecular weight apoproteins A-I and A-II were significantly decreased, but the concentration of high-molecular apo B was high. Urinary analysis revealed progression and decreasing selectivity of proteinuria with time. Thus the mechanisms leading to lipid abnormalities in CNF are multiple including stimulated hepatic lipoprotein synthesis, impaired conversion of VLDL and IDL to LDL, compositional changes, urinary loss of low-molecular apoproteins and presumably reduced LPL activity. The abnormalities indicate an increased risk of arteriosclerosis in CNF patients.
Antikainen
M
M
I Department of Pediatrics, University of Helsinki, Finland.
Holmberg
C
C
Taskinen
M R
MR
D001059:Apoproteins / Q000097:blood*; D001827:Body Height; D001835:Body Weight; D002149:Energy Intake; D005231:Fatty Acids, Unsaturated / Q000008:administration & dosage / Q000378:metabolism; D005260:Female; D006801:Humans; D007223:Infant; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D009404:Nephrotic Syndrome / Q000151:congenital* / Q000178:diet therapy / Q000378:metabolism; D012709:Serum Albumin / Q000032:analysis
D001059:Apoproteins; D005231:Fatty Acids, Unsaturated; D008074:Lipoproteins; D012709:Serum Albumin